Navigation Links
WuXi PharmaTech Appoints Ying Han to Its Board of Directors

SHANGHAI, China, Nov. 12 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it has appointed Ms. Ying Han to its Board of Directors.

From 1998 to 2006, Ms. Han worked for NASDAQ-listed Asiainfo as Chief Financial Officer and Executive Vice President. Earlier she spent 10 years in Hewlett Packard (China), serving in various functions until assuming the responsibility of Chief Controller and Business Development Director. Ms. Han is currently an advisor to Warburg Pincus, a leading global private equity firm.

"We are very pleased to welcome Ying on board to further enhance the supervision and conduct of our overall business and financial affairs," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "Ying's addition to our board with her invaluable finance and business experience will help WuXi better manage its business and financial system and ultimately increase the overall value of WuXi."

Ms. Han received a college degree in Western Accounting from Xiamen University, China.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: .

For more information, please contact:

Sherry Shao

WuXi PharmaTech (Cayman) Inc.

Tel: +86-21-5046-4002


SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Announces Third Quarter 2008 Results
2. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
3. WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008
4. WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance
5. WuXi PharmaTech Appoints Jeff Leng to Its Board of Directors
6. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
7. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
8. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
9. Warburg Pincus Acquires 5.4% of WuXi PharmaTechs Outstanding Ordinary Shares from United Overseas Bank
10. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
11. WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... and solutions to the healthcare market. The company's primary focus is on new ... and marketing strategies that are necessary to help companies efficiently bring their products ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
(Date:5/24/2016)... -- Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the ... latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Display- Ampronix News ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
Breaking Biology News(10 mins):